Literature DB >> 11268285

Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease.

D F Pauly1, T J Fraites, C Toma, H S Bayes, M L Huie, R Hirschhorn, P H Plotz, N Raben, P D Kessler, B J Byrne.   

Abstract

Pompe disease is a lethal cardioskeletal myopathy in infants and results from genetic deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). Genetic replacement of the cDNA for human GAA (hGAA) is one potential therapeutic approach. Three months after a single intramuscular injection of 10(8) plaque-forming units (PFU) of E1-deleted adenovirus encoding human GAA (Ad-hGAA), the activity in whole muscle lysates of immunodeficient mice is increased to 20 times the native level. Direct transduction of a target muscle, however, may not correct all deficient cells. Therefore, the amount of enzyme that can be transferred to deficient cells from virally transduced cells was studied. Fibroblasts from an affected patient were transduced with AdhGAA, washed, and plated on transwell culture dishes to serve as donors of recombinant enzyme. Deficient fibroblasts were plated as acceptor cells, and were separated from the donor monolayer by a 22-microm pore size filter. Enzymatic and Western analyses demonstrate secretion of the 110-kDa precursor form of hGAA from the donor cells into the culture medium. This recombinant, 110-kDa species reaches the acceptor cells, where it can be taken up by mannose 6-phosphate receptor-mediated endocytosis. It then trafficks to lysosomes, where Western analysis shows proteolytic processing to the 76- and 70-kDa lysosomal forms of the enzyme. Patient fibroblasts receiving recombinant hGAA by this transfer mechanism reach levels of enzyme activity that are comparable to normal human fibroblasts. Skeletal muscle cell cultures from an affected patient were also transduced with Ad-hGAA. Recombinant hGAA is identified in a lysosomal location in these muscle cells by immunocytochemistry, and enzyme activity is transferred to deficient skeletal muscle cells grown in coculture. Transfer of the precursor protein between muscle cells again occurs via mannose 6-phosphate receptors, as evidenced by competitive inhibition with 5 mM mannose 6-phosphate. In vivo studies in GAA-knockout mice demonstrate that hepatic transduction with adenovirus encoding either murine or human GAA can provide a depot of recombinant enzyme that is available to heart and skeletal muscle through this mechanism. Taken together, these data show that the mannose 6-phosphate receptor pathway provides a useful strategy for cell-to-cell distribution of virally derived recombinant GAA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11268285     DOI: 10.1089/104303401300042447

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  15 in total

Review 1.  Progress and problems when considering gene therapy for GSD-II.

Authors:  A Kiang; A Amalfitano
Journal:  Acta Myol       Date:  2007-07

Review 2.  Pompe disease gene therapy.

Authors:  Barry J Byrne; Darin J Falk; Christina A Pacak; Sushrusha Nayak; Roland W Herzog; Melissa E Elder; Shelley W Collins; Thomas J Conlon; Nathalie Clement; Brian D Cleaver; Denise A Cloutier; Stacy L Porvasnik; Saleem Islam; Mai K Elmallah; Anatole Martin; Barbara K Smith; David D Fuller; Lee Ann Lawson; Cathryn S Mah
Journal:  Hum Mol Genet       Date:  2011-04-25       Impact factor: 6.150

Review 3.  Preclinical Development of New Therapy for Glycogen Storage Diseases.

Authors:  Baodong Sun; Elizabeth D Brooks; Dwight D Koeberl
Journal:  Curr Gene Ther       Date:  2015       Impact factor: 4.391

4.  Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II.

Authors:  Baodong Sun; Haoyue Zhang; Daniel K Benjamin; Talmage Brown; Andrew Bird; Sarah P Young; Alison McVie-Wylie; Y-T Chen; Dwight D Koeberl
Journal:  Mol Ther       Date:  2006-09-20       Impact factor: 11.454

Review 5.  Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy.

Authors:  Barry J Byrne; David D Fuller; Barbara K Smith; Nathalie Clement; Kirsten Coleman; Brian Cleaver; Lauren Vaught; Darin J Falk; Angela McCall; Manuela Corti
Journal:  Ann Transl Med       Date:  2019-07

Review 6.  Glycogen storage disease types I and II: treatment updates.

Authors:  D D Koeberl; P S Kishnani; Y T Chen
Journal:  J Inherit Metab Dis       Date:  2007-02-16       Impact factor: 4.982

7.  Induction of tolerance to a recombinant human enzyme, acid alpha-glucosidase, in enzyme deficient knockout mice.

Authors:  Nina Raben; Kanneboyina Nagaraju; Alicia Lee; Nina Lu; Yesenia Rivera; Tejas Jatkar; John J Hopwood; Paul H Plotz
Journal:  Transgenic Res       Date:  2003-04       Impact factor: 2.788

8.  Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance.

Authors:  Baodong Sun; Andrew Bird; Sarah P Young; Priya S Kishnani; Y-T Chen; Dwight D Koeberl
Journal:  Am J Hum Genet       Date:  2007-09-21       Impact factor: 11.025

Review 9.  Therapeutic approaches in glycogen storage disease type II/Pompe Disease.

Authors:  Benedikt Schoser; Victoria Hill; Nina Raben
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

Review 10.  Gene therapy in monogenic congenital myopathies.

Authors:  Xuan Guan; Melissa A Goddard; David L Mack; Martin K Childers
Journal:  Methods       Date:  2015-10-14       Impact factor: 3.608

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.